Rick Klausner (Mike Blake/Reuters)
Updated: In broad retreat, GSK's new R&D leader abandons NY-ESO plans, pulls plug on cell therapy 2.0 alliances after losing faith
One of Hal Barron’s foundational R&D deals at GSK has come crashing down, just a couple of months after his formal departure from the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
